- Maximizing global leadership of SYFOVRE in geographic atrophy (GA)
- Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan in IC-MPGN/C3G
- Focusing research initiatives on retina and CNS
- Anticipated total cost savings of up to $300 million through 2024, which includes an approximately 25% reduction in current workforce and a reduction in external expenses
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) — Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) (the Company), a global biopharmaceutical company and leader in complement, today announced a corporate restructuring to drive growth of SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan), positioning Apellis for long-term success. This rest…
Read the full article at: https://www.globenewswire.com/news-release/2023/08/29/2733224/0/en/Apellis-Announces-Corporate-Restructuring-to-Drive-Growth-of-SYFOVRE-pegcetacoplan-injection-and-EMPAVELI-pegcetacoplan-Positioning-Company-for-Long-Term-Success.html